MX2009013069A - Tratamiento de leucemia resistente al imatinib. - Google Patents
Tratamiento de leucemia resistente al imatinib.Info
- Publication number
- MX2009013069A MX2009013069A MX2009013069A MX2009013069A MX2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- resistant leukemia
- imatinib resistant
- imatinib
- leukemia
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002411 imatinib Drugs 0.000 title abstract 2
- 208000032839 leukemia Diseases 0.000 title abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93265007P | 2007-06-01 | 2007-06-01 | |
| PCT/US2008/065215 WO2008150957A2 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013069A true MX2009013069A (es) | 2010-03-17 |
Family
ID=39639071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013069A MX2009013069A (es) | 2007-06-01 | 2008-05-30 | Tratamiento de leucemia resistente al imatinib. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11103497B2 (https=) |
| EP (4) | EP2152267A2 (https=) |
| JP (3) | JP5888853B2 (https=) |
| KR (1) | KR101493543B1 (https=) |
| CN (1) | CN101686973B (https=) |
| AU (1) | AU2008260070B9 (https=) |
| BR (1) | BRPI0812355A2 (https=) |
| CA (3) | CA2964162C (https=) |
| CL (1) | CL2008001577A1 (https=) |
| CY (2) | CY1115251T1 (https=) |
| DK (2) | DK2478905T3 (https=) |
| ES (2) | ES2881391T3 (https=) |
| HU (1) | HUE055524T2 (https=) |
| IL (1) | IL202407A0 (https=) |
| MX (1) | MX2009013069A (https=) |
| PA (1) | PA8782301A1 (https=) |
| PL (2) | PL2478905T3 (https=) |
| PT (2) | PT2478905E (https=) |
| RU (1) | RU2464026C2 (https=) |
| SI (2) | SI3002009T1 (https=) |
| TW (1) | TW200908982A (https=) |
| WO (1) | WO2008150957A2 (https=) |
| ZA (1) | ZA200908480B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055524T2 (hu) | 2007-06-01 | 2021-11-29 | Wyeth Llc | A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával |
| US9604963B2 (en) | 2011-03-04 | 2017-03-28 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| CA2902132C (en) | 2013-02-21 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| KR101733665B1 (ko) * | 2015-05-06 | 2017-05-10 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 |
| US20220388962A1 (en) * | 2019-08-22 | 2022-12-08 | Biohaven Therapeutics Ltd. | Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders |
| CN115944636A (zh) * | 2022-11-01 | 2023-04-11 | 华南师范大学 | 博舒替尼在抑制i-motif结构上的应用 |
| WO2025024311A2 (en) * | 2023-07-21 | 2025-01-30 | Icahn School Of Medicine At Mount Sinai | G9a/glp inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| MXPA03006412A (es) * | 2001-01-25 | 2003-10-15 | Bristol Myers Squibb Co | Metodos para administrar analogos de epotilona para tratamiento de cancer. |
| PT2017335E (pt) | 2001-10-05 | 2011-03-02 | Novartis Ag | Domínios da cinase abl mutados |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20050010780A1 (en) * | 2003-07-09 | 2005-01-13 | Kane John Richard | Method and apparatus for providing access to personal information |
| SG146681A1 (en) * | 2003-11-06 | 2008-10-30 | Wyeth Corp | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| RU2387653C2 (ru) * | 2005-05-16 | 2010-04-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| EP1904654A2 (en) | 2005-07-15 | 2008-04-02 | Brystol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides |
| EP1951756B1 (en) | 2005-10-06 | 2015-01-07 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2007056177A2 (en) | 2005-11-04 | 2007-05-18 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| HUE055524T2 (hu) * | 2007-06-01 | 2021-11-29 | Wyeth Llc | A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával |
-
2008
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en not_active Ceased
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active Active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
-
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
-
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
-
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
-
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013069A (es) | Tratamiento de leucemia resistente al imatinib. | |
| TN2009000303A1 (en) | Iron-hydrocarbon complex compounds | |
| MX2009007075A (es) | Metodos de uso para analogos de ciclopamina. | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| AU2009313134A8 (en) | Novel halogen-substituted compounds | |
| UA110338C2 (xx) | Хімічні сполуки | |
| MX2010009026A (es) | Uso de compuestos que se enlazan a los ligandos del receptor sigma para el tratamiento de dolor neuropatico que se desarrolla como una consecuencia de la quimioterapia. | |
| UA107796C2 (en) | Tetracyclic compound | |
| JO2860B1 (en) | Phenylendazolyl compounds | |
| MX2012001156A (es) | Moleculas que contienen boro trisustituidas. | |
| TN2011000291A1 (en) | Purine compounds | |
| SG171593A1 (en) | Inhibitors of c-fms kinase | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| MY150600A (en) | Use of opioid antagonists for treating urinary retention | |
| MX2010005395A (es) | Metodo para tratar artritis. | |
| MX2012001413A (es) | Compuestos azaheterociclicos novedosos. | |
| MX2009009490A (es) | Profarmacos novedosos. | |
| MX2012008125A (es) | Herramienta para el recubrimiento electrolitico de cojinetes de deslizamiento. | |
| PH12017500270A1 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain | |
| MX2009012096A (es) | Axomadol para tratamiento de dolor con artritis. | |
| PH12017500492A1 (en) | Crystalline bace inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |